2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2368

Analysis of Pain and Function Components in Omeract-Oarsi Strict Responders from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee
Abstract Number: 2369

Obesity and Severity of Joint Space Narrowing Are Associated with Viscosupplementation Failure in Patients with Knee Osteoarthritis. Post-Hoc Analysis of a Double-Blind, Controlled, Multicentre, Randomized Trial
Abstract Number: 2370

Factors Affecting Interval Changes in Perceived Fatigue over Five Years in Patients with Rheumatoid Arthritis Compared with Osteoarthritis
Abstract Number: 2371

Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis
Abstract Number: 2372

Effect of Oxytocin on Osteoarthritis
Abstract Number: 2373

Patient Preference for Display of Electronic Patient-Reported Outcomes in Osteoarthritis Clinical Trials: Wording Emphasis, Question Format, and Navigation Button Placement
Abstract Number: 2374

Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study
Abstract Number: 2375

Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2376

The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
Abstract Number: 2377

Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)
Abstract Number: 2378

Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
Abstract Number: 2379

Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
Abstract Number: 2380

Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study
Abstract Number: 2381

Canakinumab Monotherapy for the Treatment of Majeed Syndrome. Five-Year Experience
Abstract Number: 2382

Evaluation of Intestinal Inflammation in Children with FMF

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].